Table 2.
Other treatment or medication for recurrent hepatocellular carcinoma during the 156 wk follow-up period n (%)
| Anti-HCC therapy | Group A untreated (n = 58) | Group B 160 mg/d (n = 56) | Group C 250 mg/d (n = 54) | Total (n = 168) |
| At least one shown below | 22 (37.9) | 17 (30.4) | 22 (40.7) | 61 (36.3) |
| Chemotherapy | 3 (5.2) | 4 (7.1) | 4 (7.4) | 11 (6.5) |
| Percutaneous ethanol injection therapy | 2 (3.4) | 3 (5.4) | 3 (5.6) | 8 (4.8) |
| Radiofrequency ablation | 2 (3.4) | 3 (5.4) | 3 (5.6) | 8 (4.8) |
| Radiotherapy | 3 (5.2) | 1 (1.8) | 1 (1.9) | 5 (3.0) |
| Surgical resection | 5 (8.6) | 5 (8.9) | 7 (13.0) | 17 (10.1) |
| Transcatheter arterial chemoembolization | 18 (31.0) | 11 (19.6) | 15 (27.8) | 44 (26.2) |
| Thalidomide | 2 (3.4) | 1 (1.8) | 1 (1.9) | 4 (2.4) |
| Liver transplantation | 0 (0.0) | 1 (1.8) | 1 (1.9) | 2 (1.2) |
| Sorafenib | 1 (1.7) | 1 (1.8) | 1 (1.9) | 3 (1.8) |
| New clinical trial | 3 (5.1) | 1 (1.8) | 6 (11.3) | 10 (6.0) |
HCC: Hepatocellular carcinoma.